Results 211 to 220 of about 55,917 (264)

Atorvastatin pre-exposure in hypercholesterolemia remedies 27HC mediated dendritic cell dysfunctions in triple-negative breast cancer. [PDF]

Mol Ther Oncol
Choudhury PR, Chakravarti M, Bera S, Arora P, Sultana J, Khan MA, Biradar R, Guha A, Dhar S, Ghosh I, Ganguly N, Lasure A, Kashyap P, Das J, Mandal B, Das P, Sarkar A, Datta D, Nandi S, Alam N, Baral R, Banerjee S, Bose A.   +22 more
europepmc   +1 more source

Reversible bilateral sensorineural hearing loss associated with atorvastatin: a case report. [PDF]

J Med Case Rep
Dari MA, Wondimu ZT, Memhur SA, Assefa NC.   +3 more
europepmc   +1 more source

An LC-MS/MS Method for Simultaneous Determination of Almonertinib and Atorvastatin: Evaluating Their Drug-Drug Interactions in Rat. [PDF]

Drug Des Devel Ther
Li H, Wu H, Gao S, Cui L, Xu J, Sun J, Liu Z, Wang Z, Tao X.   +8 more
europepmc   +1 more source

Protective Effects of Policosanol and Atorvastatin Co-Supplementation Against High-Cholesterol and High-Galactose Diet-Induced Metabolic and Organ Dysfunction in Zebrafish. [PDF]

Int J Mol Sci
Cho KH, Jeon C, Bahuguna A, Kim JE, Lee SH, Lee Y, Baek SH.   +6 more
europepmc   +1 more source

A ROS‑responsive liposome for atherosclerosis treatment via combined regulation of lipid metabolism and CD47 blockade. [PDF]

Int J Pharm X
Yuan P, Tian S, Cui C, Sun C, Tang C, Gao D, Lu L, Long K, Xu F, Shu G, Zhang W, Liang X, Kong F, Li M, Li H.   +14 more
europepmc   +1 more source

Statins and reporting signals for amnesia: a pharmacovigilance analysis based on adverse event reporting database. [PDF]

Front Pharmacol
Wang L, Yang N, Ren Z.
europepmc   +1 more source

The therapeutic potential of atorvastatin in treatment of <i>G. lamblia</i> infected mice; <i>in silico</i>, parasitological, and histopathological study. [PDF]

Front Vet Sci
Mohamed K, Khodary M, Hamed D, Alhazmi A, Gattan HS, Alruhaili MH, Fadel EF, Elshabrawy HA, El-Kady AM.   +8 more
europepmc   +1 more source

Real-world comparative outcomes of atorvastatin, rosuvastatin, and lovastatin-niacin fixed-dose combination in metabolic dysfunction-associated steatotic liver disease: hepatic, metabolic, and economic perspectives. [PDF]

Diabetol Metab Syndr
Tsai YT, Mudiyanselage SPK, Tsai YJ, Maithreepala SD, Liu WC, Ko NY, Yeh JH, Wei-Lin C, Hsu PI, Chou CK, Tsai KF.   +10 more
europepmc   +1 more source